- -

: Clood. ?  »



Prevention of atherotrobmotic eventsClopidogrel is indicated in :• Adult Patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease.• Adult Patients suffering from Acute Coronary Syndrome- Non-ST segment elevation acute coronary syndrome (unstable angina/non-Q-wave myocardial infarction (MI)), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (ASA). - ST segment elevation acute myocardial infarction, in combination with ASA in medically treated patients eligible for thrombolytic therapyPrevention of atherotrobmotic and thromboembolic events in atrial fibrillation: In adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for the treatment with Vitamin K antagonists (VKA) Anti-Thrombin or Anti Factor Xa, and who have a low bleeding risk, clopidogrel is indicated in combination with ASA for the prevention of atherothrombotic and thromboembolic events, including stroke.

140 84 31971 02

Trima Israel Pharmaceutical Products Maabarot Ltd, Israel

05/2014 - 05/2024

, .
Clopidogrel as hydrogen sulfate 75 MG
Blister aluminium /aluminium 10 x TABLETS 16
Blister aluminium /aluminium 20 x TABLETS 16
Blister aluminium /aluminium 30 x TABLETS 16
Blister aluminium /aluminium 60 x TABLETS 16
Blister aluminium /aluminium 100 x TABLETS 16





? !
" !
, ,